glp-1 news today nov 2025 Who Gets the Shot? Access by State GLP-1 Agonists Market Report 2025-2033,

As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy

Eli Lilly CEO David Ricks announces details of the Medicare GLP-1 bridge program, offering weight loss medications like Fondeo and Zepbound for $50 per month to 20 million eligible Medicare Part D patients starting July 1.

From diabetes breakthroughs to weight-loss blockbusters, GLP-1 peptide APIs like Semaglutide and Tirzepatide are not just transforming patient caretheyre reshaping global strategies, reengineering supply chains, and redefining commercial po

Drug interactions : Avoid co-administration with drugs such as DPP-4 inhibitors